filmov
tv
Intellia base editing?! 🤷🏻♂️ What?!! | NTLA (stock)

Показать описание
🎦 summary ⌲ News of Intellia base editing was press released recently. This is strictly in the domain of BEAM therapeutics. I will examine their claims in a greater detail and offer my views but before that, it is pertinent to dissect the history of the animosity between the different CRISPR companies.
⏰
00:00 Summary intro
00:25 History of CRISPR-Cas technology
02:23 How the disputes started
04:44 My personal thoughts about the situation
05:20 The dispute that continues to this day
05:54 History of base editing
06:18 More drama, the Intellia base editing announcement
07:40 My thoughts about Intellia base editing
07:57 For the watch till the end gang
Audio credits ⌲ The white fox, StreamBeats by Harris Heller
Disclosure ⌲ BYang is long (and own) BEAM and ILMN stock
⏰
00:00 Summary intro
00:25 History of CRISPR-Cas technology
02:23 How the disputes started
04:44 My personal thoughts about the situation
05:20 The dispute that continues to this day
05:54 History of base editing
06:18 More drama, the Intellia base editing announcement
07:40 My thoughts about Intellia base editing
07:57 For the watch till the end gang
Audio credits ⌲ The white fox, StreamBeats by Harris Heller
Disclosure ⌲ BYang is long (and own) BEAM and ILMN stock
Intellia base editing?! 🤷🏻♂️ What?!! | NTLA (stock)
Comparing & Contrasting CRISPR-Cas9, Base Editing, and Prime Editing
Today on BiotechTV: Behind-the-scenes of base editing at Beam Therapeutics. #crispr #baseedit
$NTLA Base Editors Versus $BEAM Base Editors. (Ep. 222)
Intellia CEO on Crispr gene-editing treatment, secondary offering
BEAM stock's base editing vs. prime editing (a comparison)
Gene Editing Updates | CRISPR, Intellia, and Beam
Tessera Therapeutics: Will It Challenge Intellia, CRISPR, and Beam in Gene Editing?
Gene Editing Stocks Are Set to Explode. Here's Why.
Intellia Therapeutics Up 50% In A Single Day. A New Era For Genome Editing.(Ep. 89)
Crispr Intellia Editas sold, Beam Therapeutics the future
Using Base Editing To Edit Point Mutations | Beam Therapeutics
Intellia Therapeutics Clinical Pipeline and Q1 2021 Updates
Intellia Stock vs CRISPR Stock: The Winner Is?
Intellia Therapeutics Becomes The Most Valuable Company In Genome Editing Space. (Ep. 91)
Intellia Therapeutics CRISPR Genome Editing Treatment for ATTR
NTLA & CRSP vs BEAM & EDIT | CRISPR Patent War Explained
Breakthrough Economy: Unlocking the Potential of Gene Editing
BEAM Stock (Beam Therapeutics) brings CRISPR to the new level!
Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
Unlocking CRISPR Advances in Base Editing, Prime Editing and Future Applications
Crispr shows gene-editing success
“The Buzz'' Show: Intellia Therapeutics, Inc. (NASDAQ: NTLA) Positive Gene Editing Data
Is Gene Editing the Future?
Комментарии